DEERFIELD, Ill. / Feb 13, 2025 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Citi - 2025 Medtech & Life Sciences Access Day on Thursday, February 27, 2025. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time.
The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Tuesday, August 26, 2025.
About Baxter
Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.
| Last Trade: | US$34.73 |
| Daily Change: | 0.18 0.52 |
| Daily Volume: | 1,647,511 |
| Market Cap: | US$17.730B |
March 04, 2025 February 25, 2025 February 20, 2025 February 18, 2025 February 17, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
